Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab in Chinese Pediatric Crohn's Disease
NCT05906576Phase 4Recruiting
- Sponsor
- Taizhou Mabtech Pharmaceutical
- Start
- Sep 2023
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of infliximab in Crohn's disease, sponsored by Taizhou Mabtech Pharmaceutical. Primary endpoint: Clinical response rate at 14 weeks. Started Sep 2023; status: recruiting.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05906576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05906576.